Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Use of Cryopreserved Hepatocytes as Part of an Integrated Strategy to Characterize In Vivo Clearance for Peptide-Antibody Conjugate Inhibitors of Nav1.7 in Preclinical Species.

Foti RS, Biswas K, Aral J, Be X, Berry L, Cheng Y, Conner K, Falsey JR, Glaus C, Herberich B, Hickman D, Ikotun T, Li H, Long J, Huang L, Miranda LP, Murray J, Moyer B, Netirojjanakul C, Nixey TE, Sham K, Soto M, Tegley CM, Tran L, Wu B, Yin L, Rock DA.

Drug Metab Dispos. 2019 Aug 6. pii: dmd.119.087742. doi: 10.1124/dmd.119.087742. [Epub ahead of print]

2.

Engineering NaV1.7 Inhibitory JzTx-V Peptides with a Potency and Basicity Profile Suitable for Antibody Conjugation To Enhance Pharmacokinetics.

Murray JK, Wu B, Tegley CM, Nixey TE, Falsey JR, Herberich B, Yin L, Sham K, Long J, Aral J, Cheng Y, Netirojjanakul C, Doherty L, Glaus C, Ikotun T, Li H, Tran L, Soto M, Salimi-Moosavi H, Ligutti J, Amagasu S, Andrews KL, Be X, Lin MJ, Foti RS, Ilch CP, Youngblood B, Kornecook TJ, Karow M, Walker KW, Moyer BD, Biswas K, Miranda LP.

ACS Chem Biol. 2019 Apr 19;14(4):806-818. doi: 10.1021/acschembio.9b00183. Epub 2019 Mar 27.

PMID:
30875193
3.

Local Delivery of OncoVEXmGM-CSF Generates Systemic Antitumor Immune Responses Enhanced by Cytotoxic T-Lymphocyte-Associated Protein Blockade.

Moesta AK, Cooke K, Piasecki J, Mitchell P, Rottman JB, Fitzgerald K, Zhan J, Yang B, Le T, Belmontes B, Ikotun OF, Merriam K, Glaus C, Ganley K, Cordover DH, Boden AM, Ponce R, Beers C, Beltran PJ.

Clin Cancer Res. 2017 Oct 15;23(20):6190-6202. doi: 10.1158/1078-0432.CCR-17-0681. Epub 2017 Jul 13.

4.

AMG 580: a novel small molecule phosphodiesterase 10A (PDE10A) positron emission tomography tracer.

Chen H, Lester-Zeiner D, Shi J, Miller S, Glaus C, Hu E, Chen N, Able J, Biorn C, Wong J, Ma J, Michelsen K, Hill Della Puppa G, Kazules T, Dou HH, Talreja S, Zhao X, Chen A, Rumfelt S, Kunz RK, Ye H, Thiel OR, Williamson T, Davis C, Porter A, Immke D, Allen JR, Treanor J.

J Pharmacol Exp Ther. 2015 Feb;352(2):327-37. doi: 10.1124/jpet.114.220517. Epub 2014 Dec 11.

PMID:
25502803
5.

Regional, kinetic [(18)F]FDG PET imaging of a unilateral Parkinsonian animal model.

Silva MD, Glaus C, Hesterman JY, Hoppin J, Puppa GH, Kazules T, Orcutt KM, Germino M, Immke D, Miller S.

Am J Nucl Med Mol Imaging. 2013;3(2):129-41. Epub 2013 Mar 8.

6.

Evaluation of the antitumor effects of rilotumumab by PET imaging in a U-87 MG mouse xenograft model.

Rex K, Lewis XZ, Gobalakrishnan S, Glaus C, Silva MD, Radinsky R, Burgess TL, Gambhir SS, Coxon A.

Nucl Med Biol. 2013 May;40(4):458-63. doi: 10.1016/j.nucmedbio.2013.01.004. Epub 2013 Feb 28.

PMID:
23454250
7.

Inorganic nanoparticle-based contrast agents for molecular imaging.

Cho EC, Glaus C, Chen J, Welch MJ, Xia Y.

Trends Mol Med. 2010 Dec;16(12):561-73. doi: 10.1016/j.molmed.2010.09.004. Epub 2010 Nov 10. Review.

8.

In vivo evaluation of (64)Cu-labeled magnetic nanoparticles as a dual-modality PET/MR imaging agent.

Glaus C, Rossin R, Welch MJ, Bao G.

Bioconjug Chem. 2010 Apr 21;21(4):715-22. doi: 10.1021/bc900511j.

9.

Gold nanocages as photothermal transducers for cancer treatment.

Chen J, Glaus C, Laforest R, Zhang Q, Yang M, Gidding M, Welch MJ, Xia Y.

Small. 2010 Apr 9;6(7):811-7. doi: 10.1002/smll.200902216. No abstract available.

Supplemental Content

Support Center